Biogen Inc. (ETR:IDP)
126.10
-3.45 (-2.66%)
Oct 10, 2025, 5:35 PM CET
Biogen Revenue
Biogen had revenue of $2.65B USD in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $9.86B, up 2.14% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.86B
Revenue Growth
+2.14%
P/S Ratio
2.17
Revenue / Employee
$1.30M
Employees
7,605
Market Cap
18.49B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Biogen News
- 4 days ago - Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
- 4 days ago - Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
- 5 days ago - Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment - Nasdaq
- 5 days ago - Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
- 5 days ago - Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - Benzinga
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease - Wallstreet:Online
- 5 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PRNewsWire